SOURCE-LINKED STUDY SUMMARY
A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment.
Full paper summarizedQuality not appraised
- What was studied
- A double-blind placebo-controlled pilot tested whether nicotinamide riboside improves cognition and brain blood flow.
- Who / model studied
- 52 older adults with amnestic mild cognitive impairment were randomized; 42 completed treatment.
- Studied dose & schedule
- Oral NR 500 mg twice daily or matching placebo for 12 weeks.
- What the study found
- Blood NAD+ doubled, but cognition, total cerebral blood flow and blood pressure did not improve. Exploratory regional blood-flow signals were observed. No serious adverse events were reported.
- Limitations & context
- Small, short pilot with completer analyses. Regional findings were exploratory and uncorrected for multiple comparisons; increased blood NAD+ did not demonstrate cognitive benefit.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1002/alz.71605